Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Werewolf Therapeutics, Inc. (HOWL)
|
Add to portfolio |
|
|
|
| Price: |
$12.00
| | Metrics |
| OS: |
35.7
|
M
| |
-35
|
% ROE
|
| Market cap: |
$428
|
M
| |
-81
|
% ROIC
|
|
Net cash:
|
$98.3
|
M
| |
$2.76
|
per share
|
|
EV:
|
$330
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($42.3)
|
M
| |
|
|
|
EBIT
|
($44.0)
|
M
| |
|
|
| EPS |
($1.30)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 1.9 | 0.1 | 0.0 | 6.3 |
| Revenue growth | 1734.6% | | -100.0% | |
| Cost of goods sold | -14.5 | 0.1 | 0.0 | 12.7 |
| Gross profit | 16.4 | 0.0 | 0.0 | -6.3 |
| Gross margin | 859.6% | 0.0% | | -100.0% |
| Research and development | 53.8 | 35.3 | 16.6 | |
| General and administrative | 18.7 | 14.8 | 5.8 | 3.6 |
| EBIT | -56.1 | -50.1 | -22.4 | -9.9 |
| EBIT margin | -2937.9% | -48160.6% | | -156.7% |
| Pre-tax income | -53.8 | -50.0 | -15.0 | -10.2 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -53.8 | -201.9 | -28.2 | -18.2 |
| Net margin | -2820.2% | -194158.7% | | -287.5% |
| |
| Diluted EPS | ($1.86) | ($10.94) | ($28.08) | ($28.49) |
| Shares outstanding (diluted) | 28.9 | 18.5 | 1.0 | 0.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|